Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Tuebingen
Age
18–99
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with metastatic breast cancer in which a therapy with nab-paclitaxel was indicated by the treating physician
Treatment of nab-Paclitaxel must either have not been started yet, or first application of nab-Paclitaxel was not prior to 21 days before study entry
Female patients, age ≥18 years
Invasive breast cancer (irrespective of status of BC, e.g. TNM, receptor status etc.)
Metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging)
Patients scheduled for nab-Paclitaxel treatment in daily routine before screening
Patients, who are able and willing to sign the informed consent form
You may not be if
Patient is currently enrolled, or will enroll in an interventional clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
Clareo Health | Therapy Management With Nab-Paclitaxel in Daily Routine
